Tebentafusp

They've been engineered to be specific to peptide MHC versus something like an antibody that other people are working on where the specificity is a little bit more unknown.

And so what this first molecule was that was developed and it was approved in 2022, it's a molecule called Kimtrek or Tabentafusp approved for uveal melanoma.

It has this great specificity, but there are challenges from a manufacturing standpoint when it comes with using something like a TCR or a T cell receptor.

With a TCR or a T cell receptor, it's naturally expressed on a cell surface.